Table 4 MDSCs in HSCT
From: Myeloid-derived suppressor cells in hematological malignancies: friends or foes
HSCT or models | MDSC subgroups/phenotype definition | Clinical finding | Mechanism/intervention | Year/reference |
|---|---|---|---|---|
Unrelated HSCT, N = 51 | M-MDSCs HLA-DRlow/−CD14+ | The frequency of M-MDSCs was significantly increased after allo-HSCT, especially in patients with acute graft-versus-host disease | Blocking the IDO activity of M-MDSCs restore immune tolerance | 2013 [20] |
Unrelated-HSCT G-PB, N = 60 | M-MDSCs Linlow/negHLA-DR−CD11b+CD33+CD14+ | MDSCs in graft as only independent risk factors reducing aGvHD, MDSCs did not impact the relapse rate or the transplant-related mortality rate | Suppress alloreactive T cells | 2014 [63] |
Haplo-HSCT G-BM and PB, N = 62 | M-MDSCs Lin-HLA-DR−/lowCD33 + CD11b + CD14 + CD15dimCD16- eMDSCs Lin−HLA-DR−/lowCD33+CD11b−/lowCD14−CD15−CD16− | MDSCs in graft as independent factors that reduced the occurrence of grade II-IV aGvHD and extensive cGvHD, Delayed M-MDSC reconstitution was associated with aGvHD onset. MDSCs did not impact the relapse rate or the transplant-related mortality rate | Suppress alloreactive T cells | 2015 [64] |
MSD-HSCT G-PB or G-BM, N = 101 | MDSCs Linlow/negHLA-DR−CD33+CD11b+ | MDSCs in G-BM rather than G-PB was correlated with better GRFS and less GVHD | Immunosuppressive activity of MDSCs was similar in the G-BM and G-PB grafts | 2017 [65] |
Allo G-BM and PB, N = 100 | eMDSCs HLA-DR−/lowCD33 + CD16- | MDSCs in G-BM and G-PB as independent factors that reduced the occurrence of grade II-IV aGvHD. MDSCs did not impact the relapse rate or the transplant-related mortality rate | TGF-β signal Th2 differentiation Treg induction | 2019 [66] |